BI PRODUCT definition

BI PRODUCT means any pharmaceutical preparation or product containing a BI Compound, whether as the sole active ingredient or mixed with any other active ingredient.
View Source
BI PRODUCT means the liquid formulation of INTERFERON GAMMA 1b approved in various countries for which BII has acquired rights from GENENTECH for the treatment of Chronic Granulomatous Disease, and manufactured by BI RCV and BI Pharma KG for sale in Europe under the trademark IMUKIN®.
View Source
BI PRODUCT means the liquid formulation of INTERFERON GAMMA 1b approved in various countries of the BI Territory for the treatment of Chronic Granulomatous Disease, and manufactured by BI Austria and BI Pharma KG for sale. In Europe the BI PRODUCT is sold under the trademark IMUKIN-Registered Trademark-. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
View Source

Examples of BI PRODUCT in a sentence

  • In the event such corrections will not only be necessary for PRODUCT but as well for BI PRODUCT the appropriate allocation of the related costs between the Parties shall be determined by the PROJECT TEAM.

  • BBS and PRODUCT derived from these runs shall be used for evidencing comparability between the GENENTECH PRODUCT and the BI PRODUCT.

  • For purposes of clarity, all costs in connection with any requirements by BI RCV or a regulatory authority having jurisdiction over the manufacture, use and/or sale of the BI PRODUCT which relate specifically and solely to the BI PRODUCT (and not also to the PRODUCT) shall be solely borne by BI RCV.

  • VIDARA shall *** purchase from BI RCV, *** PRODUCT for the term of this AGREEMENT, subject to Section 3.7. Subject to restrictions that may be imposed on BI RCV with respect to VIDARA’S TECHNOLOGY or to GENENTECH TECHNOLOGY *** , this provision does not in any way restrict BI RCV’s right to manufacture *** BI PRODUCT *** .

  • IF THE CUSTOMER SUBSEQUENTLY PURCHASES A SUBSCRIPTION OF A WRITE-BACK POWER BI PRODUCT, THE CUSTOMER’S EVALUATION ACCESS SHALL IMMEDIATELY TERMINATE AND THE CUSTOMER EXPRESSLY AGREE THAT, UNLESS THE CUSTOMER HAS A SEPARATE SIGNED AGREEMENT GOVERNING THE CUSTOMER’S ACCESS TO AND USE OF WRITE-BACK POWER BI PRODUCT, THIS AGREEMENT, AND THE TERMS AND CONDITIONS HEREIN, SHALL GOVERN THE CUSTOMER’S USE OF SUCH NON-EVALUATION VERSION.

  • All costs in connection with any requirements by a HEALTH AUTHORITY which relate to the PRODUCT and the BI PRODUCT shall be equally borne by VIDARA and BI RCV.

  • InterMune shall also supply BI Austria, as reasonably requested and in reasonable amounts, with reference material, antibodies and reagents for analytical testing, and all other material reasonably available to InterMune and reasonably requested by BI Austria that may be suitable as a basis for comparison between the GENENTECH PRODUCT and the BI PRODUCT.

  • All costs in connection with any requirements by VIDARA or a HEALTH AUTHORITY which relate specifically and solely to the PRODUCT (and not also to the BI PRODUCT) shall be solely borne by VIDARA.

  • Boehringer Ingelheim International GmbH (“BII”), an Affiliate of BI and HORIZON entered into the asset purchase agreement effective as of 18 May 2016, under which HORIZON shall acquire all right, title and interest from BII to the BI PRODUCT (Imukin®) as and from 31 December 2016.

  • All costs in connection with any requirements by InterMune or a HEALTH AUTHORITY which relate specifically and solely to the PRODUCT (and not also to the BI PRODUCT) shall be solely borne by InterMune.